What it is
Prostamax is a synthetic peptide of four amino acids: lysine, glutamic acid, aspartic acid and proline. A 2012 paper gives the sequence in its title — "oligopeptide bioregulator (Lys-Glu-Asp-Pro)" (Dzhokhadze et al., PMID 23221144). It is one of the short peptides of the St Petersburg bioregulator series, each named for an organ; this one is named for the prostate.
| Property | Value | Source |
|---|---|---|
| Sequence | Lys-Glu-Asp-Pro (KEDP) | PMID 23221144, title |
| Length | 4 amino acids | — |
| Formula | C20H33N5O9 | Our calculation from the sequence |
| Molecular weight | about 487.5 | Our calculation |
| PubChem record | None found for "prostamax" or "Lys-Glu-Asp-Pro" | PubChem, 2026-11-17 |
The family resemblance is in the letters. The library's Vilon entry is Lys-Glu; Vesugen is Lys-Glu-Asp; the heart-labelled Cardiogen is a different four-letter chain, AEDR; Prostamax adds a proline to Vesugen's three to make Lys-Glu-Asp-Pro. Each is sold for a different organ. The 2004 chromatin study below also tested Cortagen, the series' brain-cortex peptide, which differs from Prostamax only in its first amino acid.
What PubMed holds — and what it does not
A search of titles and abstracts on 2026-11-17 returned five records, from 2004 to 2012. Read one by one:
| Year | Journal | What was studied | People given the peptide? |
|---|---|---|---|
| 2004 | Bull Exp Biol Med (PMID 15085253) | Leukocytes from people aged 75–88, treated in the laboratory with Vilon, Epithalon, Livagen, Prostamax and Cortagen | No |
| 2004 | Biofizika (PMID 15612551) | Heat-melting behaviour of chromatin in human lymphocytes treated with Prostamax | No |
| 2006 | Adv Gerontol (PMID 17152728) | Synthetic peptides in organ-type tissue cultures from young and old rats (title) | No |
| 2009 | Georgian Med News (PMID 19359734) | Heat output of lymphocyte cultures with copper, cadmium and Prostamax (title) | No |
| 2012 | Georgian Med News (PMID 23221144) | Chromosome markers in cells from people aged 75–86 | No |
The finding nobody selling it states: not one of the five records is about the prostate. Every study measures chromatin — how tightly DNA is wound in the nucleus — or the physical behaviour of cells in a dish. The two records whose titles alone were read (2006, 2009) are also laboratory work.
The 2012 study reports what the peptide changed in cells from people aged 75 to 86: sister chromatid exchanges rose to 12.0 per cell from 5.9, active ribosomal-gene regions (Ag-NORs) to 2.5 per cell from 0.95, and large blocks of condensed chromatin on chromosomes 1 and 9 became less frequent. The authors interpret this as Prostamax "decondensing" chromatin and releasing genes switched off in ageing.
The 2004 Bulletin study compared five peptides on leukocytes from people aged 75 to 88 and reports that all five activated ribosomal genes; Epithalon, Livagen and Prostamax also decondensed the structural chromatin around the centre of chromosome 1.
What is not established
- Any effect on the prostate. No record names a prostate measurement, a urinary symptom or a hormone level.
- Any effect in a living person. Every human sample was blood cells treated outside the body.
- Independent replication. The 2004 Bulletin study comes from the St Petersburg Institute of Bioregulation and Gerontology, and T. Lezhava is an author on four of the five records; the fifth (2006, rat tissue cultures) lists a different team. No independent group has reported a study in people.
- Safety. No study reports giving it to anyone, so nothing is known about safety in people.
ClinicalTrials.gov lists no study of Prostamax (2026-11-17; a control search for semaglutide the same day returned 836).
Where it stands
Prostamax is an unapproved research peptide with a small laboratory literature on chromatin and none on its namesake organ. Questions about prostate symptoms belong to a doctor; the library records what the compound is and what has been measured.
Sources opened 2026-11-17: PubMed E-utilities (search and the five records: abstracts of PMIDs 23221144, 15085253, 15612551; titles of 17152728, 19359734); PubChem name search; ClinicalTrials.gov API v2.
